Mainz Biomed Expands into Switzerland with labor team w
Mainz Biomed (NASDAQ:MYNZ) has announced a strategic partnership with labor team w ag to launch ColoAlert®, a DNA-based colorectal cancer (CRC) screening test, in Switzerland. This marks Mainz Biomed's first entry into the Swiss market, where thousands of new CRC cases are diagnosed annually.
The partnership combines Mainz Biomed's DNA-based diagnostic expertise with labor team w's established laboratory services network. The ColoAlert® test will be available through labor team w's healthcare provider network starting in spring 2025, offering Swiss patients access to advanced CRC screening technology.
This collaboration aims to increase CRC screening participation rates and improve early detection capabilities in Switzerland. The partnership represents an expansion of Mainz Biomed's European market presence with its flagship product ColoAlert®, which is the first DNA-based CRC screening test in Europe.
Mainz Biomed (NASDAQ:MYNZ) ha annunciato una partnership strategica con labor team w ag per lanciare ColoAlert®, un test di screening per il cancro colorettale (CRC) basato sul DNA, in Svizzera. Questo segna l'ingresso di Mainz Biomed nel mercato svizzero, dove ogni anno vengono diagnosticati migliaia di nuovi casi di CRC.
La partnership combina l'expertise diagnostica basata sul DNA di Mainz Biomed con la rete di servizi di laboratorio consolidata di labor team w. Il test ColoAlert® sarà disponibile attraverso la rete di fornitori di servizi sanitari di labor team w a partire dalla primavera del 2025, offrendo ai pazienti svizzeri l'accesso a tecnologie avanzate di screening per il CRC.
Questa collaborazione mira ad aumentare i tassi di partecipazione agli screening per il CRC e a migliorare le capacità di rilevamento precoce in Svizzera. La partnership rappresenta un'espansione della presenza di Mainz Biomed nel mercato europeo con il suo prodotto di punta ColoAlert®, che è il primo test di screening per il CRC basato sul DNA in Europa.
Mainz Biomed (NASDAQ:MYNZ) ha anunciado una asociación estratégica con labor team w ag para lanzar ColoAlert®, una prueba de detección del cáncer colorrectal (CRC) basada en ADN, en Suiza. Esto marca la primera entrada de Mainz Biomed en el mercado suizo, donde se diagnostican miles de nuevos casos de CRC cada año.
La asociación combina la experiencia diagnóstica basada en ADN de Mainz Biomed con la red de servicios de laboratorio establecida de labor team w. La prueba ColoAlert® estará disponible a través de la red de proveedores de atención médica de labor team w a partir de la primavera de 2025, ofreciendo a los pacientes suizos acceso a tecnología avanzada de detección de CRC.
Esta colaboración tiene como objetivo aumentar las tasas de participación en las pruebas de CRC y mejorar las capacidades de detección temprana en Suiza. La asociación representa una expansión de la presencia de Mainz Biomed en el mercado europeo con su producto insignia ColoAlert®, que es la primera prueba de detección de CRC basada en ADN en Europa.
Mainz Biomed (NASDAQ:MYNZ)는 스위스에서 ColoAlert®라는 DNA 기반 대장암(CRC) 선별 검사를 출시하기 위해 labor team w ag와 전략적 파트너십을 체결했다고 발표했습니다. 이는 Mainz Biomed의 스위스 시장 첫 진출로, 매년 수천 건의 새로운 CRC 사례가 진단됩니다.
이 파트너십은 Mainz Biomed의 DNA 기반 진단 전문성과 labor team w의 확립된 실험실 서비스 네트워크를 결합합니다. ColoAlert® 검사는 2025년 봄부터 labor team w의 의료 제공자 네트워크를 통해 제공되어 스위스 환자들에게 첨단 CRC 선별 검사 기술을 이용할 수 있게 합니다.
이번 협력은 스위스에서 CRC 선별 검사 참여율을 높이고 조기 발견 능력을 향상시키는 것을 목표로 합니다. 이 파트너십은 Mainz Biomed의 유럽 시장 존재감을 확대하는 것을 의미하며, ColoAlert®는 유럽 최초의 DNA 기반 CRC 선별 검사입니다.
Mainz Biomed (NASDAQ:MYNZ) a annoncé un partenariat stratégique avec labor team w ag pour lancer ColoAlert®, un test de dépistage du cancer colorectal (CRC) basé sur l'ADN, en Suisse. Cela marque la première entrée de Mainz Biomed sur le marché suisse, où des milliers de nouveaux cas de CRC sont diagnostiqués chaque année.
Ce partenariat combine l'expertise diagnostique basée sur l'ADN de Mainz Biomed avec le réseau de services de laboratoire établi de labor team w. Le test ColoAlert® sera disponible via le réseau de prestataires de soins de santé de labor team w à partir du printemps 2025, offrant aux patients suisses un accès à une technologie avancée de dépistage du CRC.
Cette collaboration vise à augmenter les taux de participation au dépistage du CRC et à améliorer les capacités de détection précoce en Suisse. Le partenariat représente une expansion de la présence de Mainz Biomed sur le marché européen avec son produit phare ColoAlert®, qui est le premier test de dépistage du CRC basé sur l'ADN en Europe.
Mainz Biomed (NASDAQ:MYNZ) hat eine strategische Partnerschaft mit labor team w ag angekündigt, um ColoAlert®, einen DNA-basierten Screening-Test auf kolorektalen Krebs (CRC), in der Schweiz einzuführen. Dies markiert den ersten Eintritt von Mainz Biomed in den Schweizer Markt, wo jährlich tausende neue CRC-Fälle diagnostiziert werden.
Die Partnerschaft kombiniert die DNA-basierte diagnostische Expertise von Mainz Biomed mit dem etablierten Netzwerk von Laborservices von labor team w. Der ColoAlert®-Test wird ab Frühjahr 2025 über das Gesundheitsdienstleister-Netzwerk von labor team w verfügbar sein und bietet Schweizer Patienten Zugang zu fortschrittlicher CRC-Screening-Technologie.
Diese Zusammenarbeit zielt darauf ab, die Teilnahmequoten an CRC-Screenings zu erhöhen und die Fähigkeiten zur frühzeitigen Erkennung in der Schweiz zu verbessern. Die Partnerschaft stellt eine Erweiterung der europäischen Marktpräsenz von Mainz Biomed mit seinem Flaggschiffprodukt ColoAlert® dar, das der erste DNA-basierte CRC-Screening-Test in Europa ist.
- First market entry into Switzerland, expanding European presence
- Partnership with established laboratory network for immediate market access
- Introduction of first DNA-based CRC screening test in Swiss market
- None.
Insights
The strategic partnership between Mainz Biomed and labor team w represents a calculated market entry into Switzerland's sophisticated healthcare market, where colorectal cancer screening presents a significant opportunity. Switzerland's healthcare spending per capita ranks among the highest globally, suggesting strong potential for premium diagnostic services adoption.
The partnership's strategic value stems from three key factors:
- Market Access Acceleration: labor team w's established presence and reputation in Swiss diagnostics provides Mainz immediate market access, bypassing the typical lengthy process of building local infrastructure and relationships.
- Technical Differentiation: ColoAlert®'s DNA-based technology offers superior detection capabilities compared to traditional fecal immunochemical tests (FIT), positioning it favorably in a market that prioritizes healthcare innovation.
- Revenue Potential: With thousands of new CRC cases annually in Switzerland and a healthcare system known for strong reimbursement policies, this market entry could generate meaningful revenue streams, particularly significant given Mainz's current market capitalization of
$13.3 million.
However, investors should note that successful market penetration will depend on several factors, including physician adoption rates, reimbursement negotiations, and competition from established screening methods. The spring 2025 launch timeline provides a clear catalyst for monitoring early market traction and adoption metrics.
This expansion aligns with broader European market trends showing increasing demand for advanced diagnostic solutions, particularly in wealthy healthcare markets like Switzerland. The partnership could serve as a blueprint for further European market entries, potentially enhancing Mainz's valuation multiple if successful implementation is demonstrated.
Partnership to Launch DNA-Based Colorectal Cancer Screening Test
BERKELEY, Calif. and MAINZ, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a strategic partnership with labor team w ag (“labor team”), a renowned diagnostic laboratory based in Goldach, Switzerland. This collaboration introduces ColoAlert®, a DNA-based colorectal cancer (CRC) screening test to the Swiss market for the very first time, marking Mainz Biomed’s initial footprint in Switzerland.
CRC remains one of the most common yet preventable forms of cancer worldwide. In Switzerland, thousands of new cases are diagnosed annually, underscoring the urgent need for early detection and prevention. The introduction of a DNA-based CRC screening test offers a transformative opportunity to increase participation rates and ensure early detection, aligning with national efforts to reduce CRC-related mortality and improve population health outcomes.
The new partnership combines Mainz Biomed’s expertise in DNA-based diagnostics with labor team w’s strong track record in delivering high-quality laboratory services. Together, the companies will provide a state-of-the-art CRC screening test to individuals across Switzerland.
“We are thrilled to partner with labor team to bring this innovative CRC screening solution to the Swiss market,” said Guido Baechler, CEO of Mainz Biomed. “By integrating our cutting-edge technology into labor team’s trusted diagnostic services, we aim to empower individuals with accessible and reliable cancer screening options, ultimately advancing public health.”
Alain Cahen, CEO of labor team, adds “the introduction of ColoAlert® on the Swiss market continues to position labor team as the top innovator of private laboratories, helping more patients access reliable diagnostic tools in key disease areas such as colon cancer screening.
This partnership also marks an important milestone for Mainz Biomed, further expanding its presence in the European market with its flagship product ColoAlert®, the first DNA-based CRC screening test in Europe. It aligns with the growing demand for personalized healthcare solutions that prioritize early intervention and prevention.
The DNA-based CRC screening test will be available through labor team w´s extensive network of healthcare providers starting in the spring 2025.
Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe and the United Arab Emirates. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.
About labor team
labor team w ag, based in Goldach in the canton of St Gallen, is one of Switzerland's leading private medical laboratories. Established in 2001 and run by medical professionals, it is now the fourth largest laboratory in Switzerland, with over 300 employees. labor team is one of the few laboratories that serves the whole of Switzerland. It provides professional services for disease prevention, diagnosis, monitoring and treatment of illnesses. The company covers every aspect of laboratory medicine and pathology. It performs medical tests and analyses in a state-of-the-art central laboratory, resulting in top quality services, a high level of flexibility and fast turnarounds.
For more information, visit: www.laborteam.ch
For media inquiries
MC Services AG
Anne Hennecke/Simone Neeten
+49 211 529252 22
mainzbiomed@mc-services.eu
For investor inquiries, please contact ir@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 9, 2024. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
FAQ
When will Mainz Biomed (MYNZ) launch ColoAlert in Switzerland?
What is the significance of MYNZ's partnership with labor team w?
How will the MYNZ-labor team w partnership affect colorectal cancer screening in Switzerland?
What makes MYNZ's ColoAlert unique in the Swiss market?
